Regencell Bioscience Holdings Limited — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/98985246-1847-4063-813a-916e9f12cba1/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-3.8M | 2024-07-01 – 2025-06-30 | evidence 0001213900-25-104686 |
| FY 2024 | $-4.7M | 2023-07-01 – 2024-06-30 | evidence 0001213900-24-090791 |
| FY 2023 | $-6.3M | 2022-07-01 – 2023-06-30 | evidence 0001013762-23-007289 |
| FY 2022 | $-7.6M | 2021-07-01 – 2022-06-30 | evidence 0001213900-22-067683 |
| FY 2021 | $-1.4M | 2020-07-01 – 2021-06-30 | evidence 0001213900-21-055256 |
| FY 2020 | $-812.4k | 2019-07-01 – 2020-06-30 | evidence 0001213900-21-055256 |
| FY 2019 | $-391.0k | 2018-07-01 – 2019-06-30 | evidence 0001213900-21-055256 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Regencell Bioscience Holdings Limited — all facts · Net Income